ArticleCancer immunology, immunotherapy : CII2026
Comparative safety of PD-1 and PD-L1 inhibitors in advanced solid tumors: a real-world cohort study with competing risk analysis.
Yu-Hsiang Shih et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.